Literature DB >> 11305974

Novel neurohumoral factors in congestive heart failure: adrenomedullin.

J G Lainchbury1.   

Abstract

Adrenomedullin is a 52-amino acid peptide that circulates in human plasma. The plasma concentrations of the peptide are increased in cardiovascular disease in proportion to the degree of hemodynamic impairment. Plasma adrenomedullin levels in heart failure, and in subjects with acute myocardial infarction, have been shown to convey independent prognostic information. Adrenomedullin has multiple biologic effects, but characteristically causes vasodilatation. The actions of adrenomedullin and the activation of this peptide in cardiovascular disease suggest it may have an important pathophysiologic role in heart failure. Manipulation of adrenomedullin or its receptor may have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11305974     DOI: 10.1007/s11886-001-0024-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  85 in total

1.  Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure.

Authors:  F Pousset; F Masson; O Chavirovskaia; R Isnard; A Carayon; J L Golmard; P Lechat; D Thomas; M Komajda
Journal:  Eur Heart J       Date:  2000-06       Impact factor: 29.983

Review 2.  Adrenomedullin and the control of fluid and electrolyte homeostasis.

Authors:  W K Samson
Journal:  Annu Rev Physiol       Date:  1999       Impact factor: 19.318

3.  Effect of exercise on plasma adrenomedullin and natriuretic peptide levels in myocardial infarction.

Authors:  A Morimoto; T Nishikimi; H Takaki; Y Okano; H Matsuoka; S Takishita; K Kitamura; A Miyata; K Kangawa; H Matsuo
Journal:  Clin Exp Pharmacol Physiol       Date:  1997-05       Impact factor: 2.557

4.  Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes.

Authors:  T Tsuruda; J Kato; K Kitamura; K Kuwasako; T Imamura; Y Koiwaya; T Tsuji; K Kangawa; T Eto
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

5.  Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature.

Authors:  T Shindo; H Kurihara; K Maemura; Y Kurihara; T Kuwaki; T Izumida; N Minamino; K H Ju; H Morita; Y Oh-hashi; M Kumada; K Kangawa; R Nagai; Y Yazaki
Journal:  Circulation       Date:  2000-05-16       Impact factor: 29.690

6.  Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension.

Authors:  N Nagaya; T Nishikimi; M Uematsu; T Satoh; H Oya; S Kyotani; F Sakamaki; K Ueno; N Nakanishi; K Miyatake; K Kangawa
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

7.  Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide.

Authors:  I Szokodi; P Kinnunen; P Tavi; M Weckström; M Tóth; H Ruskoaho
Journal:  Circulation       Date:  1998-03-24       Impact factor: 29.690

8.  The relaxant effect of adrenomedullin on particular smooth muscles despite a general expression of its mRNA in smooth muscle, endothelial and epithelial cells.

Authors:  J Nishimura; H Seguchi; C Sakihara; Y Kureishi; H Yoshimura; S Kobayashi; H Kanaide
Journal:  Br J Pharmacol       Date:  1997-01       Impact factor: 8.739

9.  Differential hormonal profiles of adrenomedullin and proadrenomedullin N-terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels.

Authors:  T Etoh; J Kato; M Takenaga; T Imamura; K Kitamura; Y Koiwaya; T Eto
Journal:  Clin Cardiol       Date:  1999-02       Impact factor: 2.882

10.  Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells.

Authors:  S Sugo; N Minamino; H Shoji; K Kangawa; K Kitamura; T Eto; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1995-02-06       Impact factor: 3.575

View more
  1 in total

Review 1.  Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure : a clinical review.

Authors:  David R Buvat de Virginy
Journal:  Heart Fail Rev       Date:  2006-12       Impact factor: 4.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.